Orgenesis (NASDAQ:ORGS) Trading Up 68.6% – Time to Buy?

by · The Cerbat Gem

Orgenesis Inc. (NASDAQ:ORGS – Get Free Report) traded up 68.6% during trading on Monday . The company traded as high as $0.59 and last traded at $0.59. 102 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 971 shares. The stock had previously closed at $0.35.

Orgenesis Stock Performance

The company’s fifty day simple moving average is $0.27 and its two-hundred day simple moving average is $0.36. The stock has a market capitalization of $3.05 million, a PE ratio of -0.05 and a beta of 3.16.

About Orgenesis

(Get Free Report)

Orgenesis, Inc is a cell and gene therapy company that develops and commercializes point-of-care manufacturing platforms for autologous and allogeneic therapies. The company offers an end-to-end solution that spans from R&D through clinical and commercial production, targeting applications in oncology, neurology, and various rare diseases. Orgenesis’ technology platforms are designed to streamline the complex processes involved in cell isolation, genetic modification, expansion and cryopreservation.

The company’s flagship offering is its automated Prodigy® platform, which integrates cell processing workflows into a closed, single-use system.

Further Reading